Drug Transport across the Blood–Brain Barrier

The blood–brain barrier (BBB) prevents the brain uptake of most pharmaceuticals. This property arises from the epithelial-like tight junctions within the brain capillary endothelium. The BBB is anatomically and functionally distinct from the blood–cerebrospinal fluid barrier at the choroid plexus. Certain small molecule drugs may cross the BBB via lipid-mediated free diffusion, providing the drug has a molecular weight <400 Da and forms <8 hydrogen bonds. These chemical properties are lacking in the majority of small molecule drugs, and all large molecule drugs. Nevertheless, drugs can be reengineered for BBB transport, based on the knowledge of the endogenous transport systems within the BBB. Small molecule drugs can be synthesized that access carrier-mediated transport (CMT) systems within the BBB. Large molecule drugs can be reengineered with molecular Trojan horse delivery systems to access receptor-mediated transport (RMT) systems within the BBB. Peptide and antisense radiopharmaceuticals are made brain-penetrating with the combined use of RMT-based delivery systems and avidin–biotin technology. Knowledge on the endogenous CMT and RMT systems expressed at the BBB enable new solutions to the problem of BBB drug transport.

[1]  E. Kohmura,et al.  Basic Fibroblast Growth Factor Prevents Thalamic Degeneration after Cortical Infarction , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  K. O’Malley,et al.  Analysis of tyrosine hydroxylase and insulin transcripts in human neuroendocrine tissues. , 1990, Brain research. Molecular brain research.

[3]  W H Oldendorf,et al.  Kinetic analysis of blood-brain barrier transport of amino acids. , 1975, Biochimica et biophysica acta.

[4]  Ulrich Friedemann,et al.  BLOOD-BRAIN BARRIER , 1942 .

[5]  Gary M Pollack,et al.  Nasal drug administration: potential for targeted central nervous system delivery. , 2005, Journal of pharmaceutical sciences.

[6]  A. Gjedde,et al.  Estimates of Michaelis-Menten Constants for the Two Membranes of the Brain Endothelium , 1984, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  M. Radeke,et al.  Distribution of Intracerebral Ventricularly Administered Neurotrophins in Rat Brain and Its Correlation with Trk Receptor Expression , 1994, Experimental Neurology.

[8]  W. Pardridge,et al.  Cloned Blood–Brain Barrier Adenosine Transporter is Identical to the Rat Concentrative Na+ Nucleoside Cotransporter CNT2 , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  W. Pardridge,et al.  Examination of Blood‐Brain Barrier Transferrin Receptor by Confocal Fluorescent Microscopy of Unfixed Isolated Rat Brain Capillaries , 1998, Journal of neurochemistry.

[10]  W. Pardridge,et al.  Brain Protection from Stroke with Intravenous TNFα Decoy Receptor-Trojan Horse Fusion Protein , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  W H Oldendorf,et al.  TRANSPORT OF METABOLIC SUBSTRATES THROUGH THE BLOOD‐BRAIN BARRIER 1 , 1977, Journal of neurochemistry.

[12]  Y. Sugiyama,et al.  Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. , 1996, The Journal of pharmacology and experimental therapeutics.

[13]  W. Pardridge,et al.  Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  Ajay,et al.  Designing libraries with CNS activity. , 1999, Journal of medicinal chemistry.

[15]  W. Pardridge.  Recent advances in blood-brain barrier transport. , 1988, Annual review of pharmacology and toxicology.

[16]  W. Pardridge,et al.  Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. , 1999, Bioconjugate chemistry.

[17]  Ronald T. Borchardt,et al.  Hydrogen Bonding Potential as a Determinant of the in Vitro and in Situ Blood–Brain Barrier Permeability of Peptides , 1994, Pharmaceutical Research.

[18]  A. Vorbrodt.  Ultracytochemical characterization of anionic sites in the wall of brain capillaries , 1989, Journal of neurocytology.

[19]  W. Pardridge,et al.  Human Insulin Receptor Monoclonal Antibody Undergoes High Affinity Binding to Human Brain Capillaries in Vitro and Rapid Transcytosis Through the Blood–Brain Barrier in Vivo in the Primate , 1995, Pharmaceutical Research.

[20]  W. Pardridge,et al.  Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. , 2007, Bioconjugate chemistry.

[21]  R. Fine,et al.  Receptor-mediated endocytosis of transferrin at the blood-brain barrier. , 1993, Journal of cell science.

[22]  W. Pardridge,et al.  Human blood-brain barrier insulin-like growth factor receptor. , 1988, Metabolism: clinical and experimental.

[23]  W. Pardridge,et al.  Human Blood—Brain Barrier Insulin Receptor , 1985, Journal of neurochemistry.

[24]  B. Swartz,et al.  The Human Brain GLUT1 Glucose Transporter: Ultrastructural Localization to the Blood—Brain Barrier Endothelia , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[25]  E. Brittebo,et al.  Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[26]  W. R. Lieb,et al.  Non-stokesian nature of transverse diffusion within human red cell membranes , 2005, The Journal of Membrane Biology.

[27]  THE LATE PROFESSOR EDWIN GOLDMANN'S INVESTIGATIONS ON THE CENTRAL NERVOUS SYSTEM BY VITAL STAINING , 1913, British medical journal.

[28]  B. Engelhardt,et al.  Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. , 2000, The Journal of pharmacology and experimental therapeutics.

[29]  W. Mark Saltzman,et al.  Chemotherapeutic Drugs Released from Polymers: Distribution of 1,3-bis(2-chloroethyl)-l-nitrosourea in the Rat Brain , 1996, Pharmaceutical Research.

[30]  Suzanne Hermeling,et al.  Targeting the Cerebrovascular Large Neutral Amino Acid Transporter (LAT1) Isoform Using a Novel Disulfide-Based Brain Drug Delivery System , 2007, Drug delivery.

[31]  A. Ghose,et al.  A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. , 1999, Journal of combinatorial chemistry.

[32]  T. Reese,et al.  JUNCTIONS BETWEEN INTIMATELY APPOSED CELL MEMBRANES IN THE VERTEBRATE BRAIN , 1969, The Journal of cell biology.

[33]  Qing-hui Zhou,et al.  Monoclonal Antibody-Glial-Derived Neurotrophic Factor Fusion Protein Penetrates the Blood-Brain Barrier in the Mouse , 2010, Drug Metabolism and Disposition.

[34]  K. Kristensson,et al.  Uptake of exogenous proteins in mouse olfactory cells , 2004, Acta Neuropathologica.

[35]  W. Pardridge,et al.  Biopharmaceutical drug targeting to the brain , 2010, Journal of drug targeting.

[36]  R. Weaver,et al.  Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. , 2009, Biochemical pharmacology.

[37]  Luca Cucullo,et al.  Pattern of P450 expression at the human blood–brain barrier: Roles of epileptic condition and laminar flow , 2010, Epilepsia.

[38]  W. Pardridge,et al.  Transport of [125I]transferrin through the rat blood-brain barrier , 1995, Brain Research.

[39]  W. Pardridge.  The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[40]  W. Pardridge,et al.  Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. , 2012, Methods in enzymology.

[41]  M. Fujimiya,et al.  Extrapancreatic insulin-producing cells in multiple organs in diabetes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[42]  H. Lodish,et al.  Sequence and structure of a human glucose transporter. , 1985, Science.

[43]  Qing-hui Zhou,et al.  Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. , 2010, Journal of biotechnology.

[44]  Priz.-Doz. Dr. Thomas Bär.  The Vascular System of the Cerebral Cortex , 1980, Advances in Anatomy, Embryology and Cell Biology.

[45]  W. Pardridge,et al.  GLUT-1 glucose transporter is present within apical and basolateral membranes of brain epithelial interfaces and in microvascular endothelia with and without tight junctions. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[46]  Yi Ai,et al.  Point source concentration of GDNF may explain failure of phase II clinical trial , 2006, Experimental Neurology.

[47]  C. Patlak,et al.  Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. , 1975, The Journal of pharmacology and experimental therapeutics.

[48]  W. Pardridge,et al.  Mediated efflux of IgG molecules from brain to blood across the blood–brain barrier , 2001, Journal of Neuroimmunology.

[49]  H. Merritt,et al.  The cerebrospinal fluid , 1938 .

[50]  H. Saji,et al.  Novel 18F-labeled benzofuran derivatives with improved properties for positron emission tomography (PET) imaging of β-amyloid plaques in Alzheimer's brains. , 2011, Journal of medicinal chemistry.

[51]  Meindert Danhof,et al.  Critical factors of intracerebral microdialysis as a technique to determined the pharmacokinetics of drugs in rat brain , 1994, Brain Research.

[52]  Bradley E. Enerson,et al.  Expression of monocarboxylate transporter MCT1 by brain endothelium and glia in adult and suckling rats. , 1997, The American journal of physiology.

[53]  H. Merritt,et al.  The cerebrospinal fluid , 1935 .

[54]  J. Galicich,et al.  Formation and absorption of cerebrospinal fluid in man. , 1968, Brain : a journal of neurology.

[55]  L. McCullough,et al.  The Blood–Brain Barrier: Geriatric Relevance of a Critical Brain–Body Interface , 2010, Journal of the American Geriatrics Society.

[56]  R. Egleton,et al.  Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability , 2001, Peptides.

[57]  D. Greenblatt,et al.  Benzodiazepine concentrations in brain directly reflect receptor occupancy: studies of diazepam, lorazepam, and oxazepam , 2005, Psychopharmacology.

[58]  W. Oldendorf,et al.  Independent blood-brain barrier transport systems for nucleic acid precursors. , 1975, Biochimica et biophysica acta.

[59]  H. Reiber,et al.  Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. , 1987, Clinica chimica acta; international journal of clinical chemistry.

[60]  Qing-hui Zhou,et al.  Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein. , 2011, Bioconjugate chemistry.

[61]  Q. Smith,et al.  Identification of the Cationic Amino Acid Transporter (System y+) of the Rat Blood‐Brain Barrier , 1993, Journal of neurochemistry.

[62]  W. Pardridge,et al.  Abeta(1-40) peptide radiopharmaceuticals for brain amyloid imaging: (111)In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections. , 2000, Bioconjugate chemistry.

[63]  A. Seelig,et al.  Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion , 1998, The Journal of Membrane Biology.

[64]  R. Béliveau,et al.  New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. , 2010, Journal of medicinal chemistry.

[65]  Richard J. Davidson,et al.  The Distribution of D2/d3 Receptor Binding in the Adolescent Rhesus Monkey Using Small Animal Pet Imaging , 2022 .

[66]  K. Matsubara,et al.  Carrier-mediated processes in blood–brain barrier penetration and neural uptake of paraquat , 2001, Brain Research.

[67]  W. Pardridge,et al.  Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood‐brain barrier , 2008, Biotechnology and bioengineering.

[68]  W. Pardridge,et al.  Comparison of Blood-Brain Barrier Transport of Glial-Derived Neurotrophic Factor (GDNF) and an IgG-GDNF Fusion Protein in the Rhesus Monkey , 2009, Drug Metabolism and Disposition.

[69]  W. Pardridge,et al.  Blood-brain barrier transcytosis of insulin in developing rabbits , 1987, Brain Research.

[70]  W. Pardridge,et al.  Selective expression of the large neutral amino acid transporter at the blood-brain barrier. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[71]  W. Pardridge,et al.  The brain-type glucose transporter mRNA is specifically expressed at the blood-brain barrier. , 1990, Biochemical and biophysical research communications.

[72]  W. Pardridge,et al.  Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. , 1997, The Journal of clinical investigation.

[73]  C Crone,et al.  Facilitated transfer of glucose from blood into brain tissue. , 1965, The Journal of physiology.

[74]  W. Oldendorf.  Cerebrospinal fluid formation and circulation. , 1972, Progress in nuclear medicine.

[75]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[76]  W. Pardridge,et al.  Human blood-brain barrier transferrin receptor. , 1987, Metabolism: clinical and experimental.

[77]  W. Pardridge,et al.  Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins , 1990, Journal of neurochemistry.

[78]  W. Jefferies,et al.  A Unique Carrier for Delivery of Therapeutic Compounds beyond the Blood-Brain Barrier , 2008, PloS one.

[79]  W H Oldendorf,et al.  Blood-Brain Barrier: Penetration of Morphine, Codeine, Heroin, and Methadone after Carotid Injection , 1972, Science.

[80]  R. Aird.  A study of intrathecal, cerebrospinal fluid-to-brain exchange , 1984, Experimental Neurology.

[81]  A. Bangham,et al.  Diffusion of Small Non-Electrolytes across Liposome Membranes , 1972, Nature.

[82]  Randolph M. Johnson,et al.  Hyperplastic Changes within the Leptomeninges of the Rat and Monkey in Response to Chronic Intracerebroventricular Infusion of Nerve Growth Factor , 1997, Experimental Neurology.

[83]  W. Pardridge,et al.  Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: an electron microscopic immunogold study. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[84]  W. Wilson,et al.  Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain. , 1992, Cancer research.

[85]  W H Oldendorf,et al.  Kinetics of blood-brain transport of hexoses. , 1975, Biochimica et biophysica acta.

[86]  P. Nielsen,et al.  Antisense properties of duplex- and triplex-forming PNAs. , 1996, Nucleic acids research.

[87]  W. Pardridge,et al.  Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[88]  H. Träuble,et al.  The movement of molecules across lipid membranes: A molecular theory , 1971, The Journal of Membrane Biology.

[89]  W. Pardridge,et al.  Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. , 2008, Bioconjugate chemistry.

[90]  U. Bickel,et al.  In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[91]  V J Cunningham,et al.  KINETICS OF BLOOD‐BRAIN BARRIER TRANSPORT OF PYRUVATE, LACTATE AND GLUCOSE IN SUCKLING, WEANLING AND ADULT RATS , 1979, Journal of neurochemistry.

[92]  W. Pardridge,et al.  Developmental modulation of blood-brain barrier and choroid plexus GLUT1 glucose transporter messenger ribonucleic acid and immunoreactive protein in rabbits. , 1993, Endocrinology.

[93]  W. Pardridge,et al.  Rapid transferrin efflux from brain to blood across the blood–brain barrier , 2001, Journal of neurochemistry.

[94]  David S. Miller,et al.  Rapid, Reversible Modulation of Blood–Brain BarrierP-Glycoprotein Transport Activity by Vascular Endothelial Growth Factor , 2010, The Journal of Neuroscience.

[95]  W. Pardridge,et al.  Drug Targeting of Erythropoietin Across the Primate Blood-Brain Barrier with an IgG Molecular Trojan Horse , 2010, Journal of Pharmacology and Experimental Therapeutics.

[96]  Victor A. Levin,et al.  RELATIONSHIP OF OCTANOL/WATER PARTITION COEFFICIENT AND MOLECULAR WEIGHT TO RAT BRAIN CAPILLARY PERMEABILITY , 1980 .

[97]  Takashi Suzuki,et al.  Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors , 2011, Journal of neurochemistry.

[98]  H. Guchelaar,et al.  Direct access of drugs to the human brain after intranasal drug administration? , 2003, Neurology.

[99]  W. Pardridge,et al.  Expression of the neonatal Fc receptor (FcRn) at the blood–brain barrier , 2002, Journal of neurochemistry.

[100]  C. Patlak,et al.  Drainage of interstitial fluid from different regions of rat brain. , 1984, The American journal of physiology.

[101]  W. Pardridge,et al.  The Blood-brain barrier : cellular and molecular biology , 1993 .

[102]  Yanfeng Wang,et al.  The Simultaneous Estimation of the Influx and Efflux Blood-Brain Barrier Permeabilities of Gabapentin Using a Microdialysis-Pharmacokinetic Approach , 1996, Pharmaceutical Research.

[103]  U. Haberkorn,et al.  The pharmacokinetics of cell-penetrating peptides. , 2010, Molecular pharmaceutics.

[104]  J. Crawley,et al.  Centrally administered cholecystokinin suppresses feeding through a peripheral-type receptor mechanism. , 1991, The Journal of pharmacology and experimental therapeutics.

[105]  D. Selkoe,et al.  LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-β peptide in a blood–brain barrier in vitro model , 2008, Neurobiology of Disease.

[106]  J R Chretien,et al.  Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. , 1998, Journal of drug targeting.

[107]  W. Pardridge,et al.  Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. , 1997, The Journal of clinical investigation.

[108]  T. Broman.  THE POSSIBILITIES OF THE PASSAGE OF SUBSTANCES FROM THE BLOOD TO THE CENTRAL NERVOUS SYSTEM (Is there a Blood‐Brain‐Barrier and a Blood‐Cerebrospinal Fluid‐Barrier?) , 1941 .

[109]  W. Pardridge,et al.  Molecular cloning of the bovine blood-brain barrier glucose transporter cDNA and demonstration of phylogenetic conservation of the 5′-untranslated region , 1990, Molecular and Cellular Neuroscience.

[110]  H. Vinters,et al.  Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[111]  J. Diamond,et al.  Molecular forces governing non-electrolyte permeation through cell membranes , 1969, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[112]  J. Diamond,et al.  Comparison of nonelectrolyte permeability patterns in several epithelia , 2005, The Journal of Membrane Biology.

[113]  R. Hedrich,et al.  Proton-driven sucrose symport and antiport are provided by the vacuolar transporters SUC4 and TMT1/2. , 2011, The Plant journal : for cell and molecular biology.

[114]  H. Duvernoy,et al.  The vascularization of the human cerebellar cortex , 1983, Brain Research Bulletin.

[115]  H. Berendsen,et al.  Proton transport across transient single-file water pores in a lipid membrane studied by molecular dynamics simulations. , 1996, Biophysical journal.

[116]  W. Pardridge,et al.  Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood–brain barrier delivery in the mouse , 2009, Biotechnology and bioengineering.

[117]  W. Pardridge,et al.  Imaging amyloid plaque in Alzheimer's disease brain with a biotinylated Aβ peptide radiopharmaceutical conjugated to an IgG-avidin fusion protein. , 2012, Bioconjugate chemistry.

[118]  W. Pardridge,et al.  Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. , 1999, Cancer research.

[119]  W H Oldendorf,et al.  Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. , 1971, The American journal of physiology.

[120]  R. Rudick,et al.  Clearance of albumin from mouse subarachnoid space: a measure of CSF bulk flow , 1982, Journal of Neuroscience Methods.

[121]  K. Fishman,et al.  Fate of adrenal cortical steroids following intrathecal injection , 1965, Neurology.

[122]  A. McCall,et al.  Distribution of glucose transporter messenger RNA transcripts in tissues of rat and man. , 1987, The Journal of clinical investigation.

[123]  M. Birnbaum,et al.  Cloning and characterization of a cDNA encoding the rat brain glucose-transporter protein. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[124]  W. Oldendorf,et al.  Blood-brain barrier: interface between internal medicine and the brain. , 1986, Annals of internal medicine.

[125]  W. Pardridge,et al.  Humanization of anti‐human insulin receptor antibody for drug targeting across the human blood–brain barrier , 2007, Biotechnology and bioengineering.

[126]  D. Knopman,et al.  Developmental Aspects of the Intracerebral Microvasculature and Perivascular Spaces: Insights into Brain Response to Late-Life Diseases , 2011, Journal of neuropathology and experimental neurology.

[127]  W. Pardridge,et al.  Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative western blotting and in situ hybridization. , 1990, The Journal of biological chemistry.

[128]  W. Pardridge,et al.  Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. , 1979, The Journal of clinical investigation.

[129]  T. Terasaki,et al.  Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. , 2011, Journal of pharmaceutical sciences.